newsfilter
← Latest News
Business Wire·

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

Transaction will result in OmniAb becoming an independent publicly traded company Ligand's shareholders to receive 100% of Ligand's shares in OmniAb through a tax-free distribution immediately prior to the merger Ligand Pharmaceuticals Incorporate